A5026915222- Amyloidosis: Diagnosis, Treatment, Outcomes
- Parathyroid Disorders and Treatments
- Peptidase Inhibition and Analysis
- Cardiovascular Function and Risk Factors
- Eosinophilic Disorders and Syndromes
- Sarcoidosis and Beryllium Toxicity Research
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Cardiomyopathy and Myosin Studies
- Medical Imaging and Pathology Studies
- Cardiac Structural Anomalies and Repair
- Neuroendocrine Tumor Research Advances
- Mechanical Circulatory Support Devices
- Heart Failure Treatment and Management
- Cardiac Imaging and Diagnostics
- Cardiac electrophysiology and arrhythmias
- Atrial Fibrillation Management and Outcomes
- Pneumocystis jirovecii pneumonia detection and treatment
- Dermatological and Skeletal Disorders
- IgG4-Related and Inflammatory Diseases
- Transplantation: Methods and Outcomes
- Cardiac Valve Diseases and Treatments
- Crystallography and molecular interactions
- Cardiac Arrhythmias and Treatments
- Potassium and Related Disorders
- Crystallization and Solubility Studies
Cleveland Clinic
2016-2025
Amyloidosis Foundation
2020-2025
University College London
2024
Pfizer (United States)
2024
Icahn School of Medicine at Mount Sinai
2023
New York University
2023
Saint Luke's Hospital
2022
Cleveland Clinic Florida
2022
Summa Health System
2021
Queen's University Belfast
2020-2021
Transthyretin amyloid cardiomyopathy is caused by the deposition of transthyretin fibrils in myocardium. The occurs when wild-type or variant becomes unstable and misfolds. Tafamidis binds to transthyretin, preventing tetramer dissociation amyloidogenesis.In a multicenter, international, double-blind, placebo-controlled, phase 3 trial, we randomly assigned 441 patients with 2:1:2 ratio receive 80 mg tafamidis, 20 placebo for 30 months. In primary analysis, hierarchically assessed all-cause...
The diagnosis of cardiac amyloidosis (CA) is challenging owing to vague symptomatology and non-specific echocardiographic findings.To describe regional patterns in longitudinal strain (LS) using two-dimensional speckle-tracking echocardiography CA test the hypothesis that differences would help differentiate from other causes increased left ventricular (LV) wall thickness.55 consecutive patients with were compared 30 control LV hypertrophy (n=15 hypertrophic cardiomyopathy, n=15 aortic...
Transthyretin (TTR) amyloidosis is an underdiagnosed disease caused by destabilization of TTR due to pathogenic mutations or aging. Both and protective illuminate mechanisms potential interventions. AG10 a selective, oral stabilizer under development for transthyretin cardiomyopathy (ATTR-CM) that mimics mutation.This randomized, double-blind, placebo-controlled study evaluated safety, tolerability, pharmacokinetics, pharmacodynamics in ATTR-CM patients with symptomatic, chronic heart...
Transthyretin amyloid cardiomyopathy is characterized by the deposition of misfolded monomeric transthyretin (TTR) in heart. Acoramidis a high-affinity TTR stabilizer that acts to inhibit dissociation tetrameric and leads more than 90% stabilization across dosing interval as measured ex vivo.
Tafamidis is an effective treatment for transthyretin amyloid cardiomyopathy (ATTR-CM) in the Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT). While ATTR-ACT was not designed a dose-specific assessment, further analysis from and its long-term extension study (LTE) can guide determination of optimal dose.In ATTR-ACT, patients were randomized (2:1:2) to tafamidis 80 mg, 20 or placebo 30 months. Patients completing could enrol LTE (with placebo-treated mg; 2:1) all subsequently switched...
Tafamidis improved survival and decreased cardiovascular hospitalizations in the ATTR-ACT trial. Due to recognition earlier diagnosis, epidemiology of transthyretin amyloid cardiomyopathy (ATTR-CM) is rapidly evolving. The authors sought evaluate contemporary long-term outcomes patients with ATTR-CM treated tafamidis. Patients who received at least 1 dose tafamidis between 2018 2021 5 amyloidosis centers United States were enrolled. Primary outcome was all-cause mortality. Among 624...
Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed chronic disease associated with progressive heart failure that results in impaired quality of life, repeated hospitalizations, and premature death. Acoramidis a selective, oral transthyretin stabilizer recently approved by the U.S. Food Drug Administration for treatment ATTR-CM. In phase 3, randomized, double-blind study (ATTRibute-CM [Efficacy Safety AG10 Subjects With Amyloid Cardiomyopathy]), acoramidis was well tolerated...
In this contribution, we describe how the supramolecular synthon approach can be used for discovery of novel crystal forms and enhancing relevant preclinical properties a low solubility antiepileptic drug, lamotrigine (6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine). Ten are reported: methylparaben cocrystal form I (1:1) (1), II (2), nicotinamide (3), monohydrate (1:1:1) (4), saccharin salt (5), adipate (2:1) (6), malate (7), nicotinate dimethanol solvate (1:1:2) (8), (1:2) (9), ethanol...
<h3>Objective</h3> Cardiac amyloidosis (CA) is a rapidly progressive disease that portends poor prognosis. Our objective was to evaluate the prognostic impact of relative regional strain ratio (RRSR, measure apical sparing longitudinal (LS)) in CA. <h3>Methods</h3> This retrospective study evaluating 97 patients with CA from 2004 2013. Patients were included if they met criteria for based on endomyocardial biopsy or advanced imaging coupled either extracardiac genetic analysis. Baseline...
Meloxicam is a nonsteroidal anti-inflammatory drug prescribed for rheumatoid arthritis, osteoarthritis, postoperative pain and fever. exhibits low solubility in acidic aqueous media slow onset of action biological subjects. An oral dosage form meloxicam with enhanced desired to enable faster its use mild-to-medium-level acute relief. With this mind, we examine the pharmacokinetics 12 cocrystals carboxylic acids. Dissolution studies were performed pH 6.5 phosphate buffer solutions at 37 °C....